Trials / Not Yet Recruiting
Not Yet RecruitingNCT06426758
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Xiao-Ming Mao · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood. We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In order to confirm lytic reactivation of EBV, the number of EBV DNA copies,mRNA and protein expression of immediate-early, early and late lytic EBV genes,EBV +TRAb+cells will be tested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated.
Detailed description
The lytic reactivation of latent EBV play importment roles in development of GD and recurrence rate of hyperthyroidism. The aim of this study is to evaluate the proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism. All patients satisfied the diagnostic criteria for GD. The diagnotic remission of hyperthyroidism was included of clinical symptoms and elevated FT3 and FT4, the patients who have been received antithyroid drugs (methimazole or propylthiouracil) titration treatment for 18 or more months and of antithyroid drugs titration treatment and withdrawal antithyroid drugs at least 3 months. The evaluation of lytic reactivation of latent EBV including EBV DNA copies,mRNA and protein expression of immediate-early, early and late lytic genes,and EBV +TRAb+cells. The EBV DNA copies was tested with PCR, mRNA and protein expression of immediate-early, early and late lytic EBV genes were analysed with RT-qPCR or Western blot and EBV +TRAb+cells were evaluated with flow cytometry. All statistical tests were performed using GraphPad Prism V8.0.
Conditions
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
- First posted
- 2024-05-23
- Last updated
- 2024-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06426758. Inclusion in this directory is not an endorsement.